Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-03-08
DOI
10.3389/fimmu.2022.797589
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
- (2021) Wilfredo F. Garcia-Beltran et al. CELL
- Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
- (2021) Pengfei Wang et al. NATURE
- Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera
- (2021) Xuping Xie et al. NATURE MEDICINE
- Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine — Preliminary Report
- (2021) Kai Wu et al. NEW ENGLAND JOURNAL OF MEDICINE
- The effect of the D614G substitution on the structure of the spike glycoprotein of SARS-CoV-2
- (2021) Donald J. Benton et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities
- (2021) Maria G. Noval et al. Scientific Reports
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
- (2021) David S. Khoury et al. NATURE MEDICINE
- Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
- (2021) Jerald Sadoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity
- (2021) Chihiro Motozono et al. Cell Host & Microbe
- Serum Neutralizing Activity of mRNA-1273 Against SARS-CoV-2 Variants
- (2021) Angela Choi et al. JOURNAL OF VIROLOGY
- Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2
- (2021) Matthias Tenbusch et al. LANCET INFECTIOUS DISEASES
- Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
- (2021) Delphine Planas et al. NATURE
- Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
- (2021) Galit Alter et al. NATURE
- BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants
- (2021) Jianying Liu et al. NATURE
- Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
- (2021) Joana Barros-Martins et al. NATURE MEDICINE
- Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination
- (2021) Dan H. Barouch et al. NEW ENGLAND JOURNAL OF MEDICINE
- Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes
- (2021) Takuya Tada et al. mBio
- The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance
- (2021) Izumi Kimura et al. Cell Reports
- Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding
- (2020) Tyler N. Starr et al. CELL
- Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy
- (2020) Hongjing Gu et al. SCIENCE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2
- (2020) Takuya Tada et al. Cell Reports
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started